Lutikizumab
- Generic Name
- Lutikizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1791411-57-8
- Unique Ingredient Identifier
- 15FAZ725S0
- Background
Lutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT06718101
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 500
- Registration Number
- NCT06548542
- Locations
- 🇵🇹
2CA-Braga, Hospital de Braga /ID# 265894, Braga, Portugal
🇵🇹Unidade Local de Saude de Coimbra, EPE /ID# 267240, Coimbra, Portugal
🇵🇹Unidade Local de Saude de Lisboa Ocidental, EPE /ID# 267242, Lisboa, Portugal
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT06524635
- Locations
- 🇺🇸
University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor, Michigan, United States
🇺🇸Physioseq, LLC /ID# 267266, Sacramento, California, United States
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1280
- Registration Number
- NCT06468228
- Locations
- 🇨🇳
Linkou Chang Gung Memorial Hospital /ID# 264620, Taoyuan City, Taiwan
🇨🇳National Taiwan University Hospital /ID# 264618, Taipei City, Taipei, Taiwan
🇨🇳Mackay Memorial Hospital /ID# 263661, Taipei City, Taiwan
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT06257875
- Locations
- 🇵🇱
Centrum Medyczne Melita Medical /ID# 258379, Wrocław, Dolnoslaskie, Poland
🇵🇱Centrum Medyczne LukaMed Joanna Luka /ID# 258457, Chojnice, Pomorskie, Poland
🇵🇷Caribbean Medical Research Center /ID# 268395, San Juan, Puerto Rico
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 210
- Registration Number
- NCT05139602
- Locations
- 🇺🇸
Skin Care Research Boca Raton /ID# 240758, Boca Raton, Florida, United States
🇺🇸Duplicate_Skin Specialists, PC /ID# 240804, Omaha, Nebraska, United States
🇺🇸Schweiger Dermatology, P.C. /ID# 240900, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.